BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, January 27, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

March 27, 2008

View Archived Issues

New agents for arthritis and other antiinflammatory conditions reported in recent patents

Read More

Novel analgesic agents reported in recent patent literature

Read More

Recent Biovitrum patent describes novel antiobesity agents

Read More

Treanda receives FDA approval for CLL

Read More

RXR agonist NRX-4204 begins phase I trial

Read More

CHMP recommends approval of Zevalin as first-line consolidation therapy

Read More

Medicago's H5N1 vaccine protects against multiple strains of avian flu

Read More

Ceragenix and FirstPoint enter license agreement for CSA-54 in HIV

Read More

Pivotal diabetes study of mitiglinide completes enrollment

Read More

FDA clears Third Wave's InPlex molecular test for cystic fibrosis

Read More

Corcept initiates phase III trial of Corlux for the psychotic features of psychotic depression

Read More

Depomed initiates dosing in phase III clinical trial of Gabapentin GR in postherpetic neuralgia

Read More

CHMP rejects UCB's appeal over refusal of E.U. MAA for Cimzia in Crohn's disease

Read More

NanoBio reports promising results from phase II study of NB-002 for onychomycosis

Read More

FDA grants clearance to ProNAi to initiate phase I clinical trials of PNT-2258 for cancer

Read More

Acceleron and Celgene receive Hart-Scott-Rodino clearance for ACE-011 collaboration

Read More

SIGA Technologies submits EUA application to the FDA for smallpox antiviral ST-246

Read More

BioLineRx reports results from phase I/II clinical trial of BL-1040 for acute MI

Read More

Thyroid-stimulating hormone reverses ovariectomy-induced bone loss in rats

Read More

JNJ-27390467, a novel tryptase inhibitor with efficacy in models of allergic asthma

Read More

Novel CCR5 antagonist profiled at Novartis

Read More

Repligen commences phase III RG-1068 trial for pancreatic MRI imaging

Read More

FDA approves IND application for use of Davanat to treat a breast cancer patient

Read More

Presidio obtains exclusive worldwide rights to XTL's NS5A program for HCV

Read More

Sosei to temporarily halt AD-923 phase III studies in cancer breakthrough pain

Read More

First Committee on New Drugs passes AnGes' NDA for Naglazyme for MPS VI

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 26, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 23, 2026.
  • DNA mutations or genetic disorder concept art

    Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

    BioWorld Science

    Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

  • Illustration of human body surrounded by DNA, cell and drug icons

    Cell/gene therapy sector now sustainable; China competition mounting

    BioWorld
    There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
  • Dice spelling out D-E-A-L-?, yes, no

    Muted and missing M&As: JPM deals absent in 2026

    BioWorld
    For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing